The identification of GCK-activating mutations in hyperinsulinemic hypoglycemia patients may be useful for a deeper understanding of the pathophysiology involved and preventing unnecessary glucocorticoid therapy. This evidence concerns the gene GCK and hyperinsulinemic hypoglycemia.